Clinical Trials Logo

Clinical Trial Summary

A two-part study for NAFLD subjects with normal liver functions and in general good health to be treated with CM-101 or matching placebo and NAFLD/NASH Activity Score (NAS) < 3 that are in general good health and have normal liver functions to be treated with CM-101.


Clinical Trial Description

This study is designed to assess the safety and preliminary pharmacodynamics of repeated administrations of CM-101 in two subject populations. The objective of part one of this study is to demonstrate that repeated treatment with CM-101 will be safe and well tolerated in NAFLD subjects that have normal liver functions and are in general good health. A second expansion part will be carried out that will include patients with NAFLD/NASH Activity Score (NAS) < 3 that are in general good health and have normal liver functions. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06044467
Study type Interventional
Source ChemomAb Ltd.
Contact
Status Completed
Phase Phase 1
Start date December 11, 2018
Completion date April 27, 2020

See also
  Status Clinical Trial Phase
Withdrawn NCT06138327 - A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria Phase 1
Completed NCT01045499 - LAGB as a Treatment for Morbid Obesity in Adolescents N/A
Completed NCT03674476 - An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function Phase 1
Not yet recruiting NCT05495139 - Gastric Bypass Stent Small-Sample-Size Study For Nonalcoholic Fatty Liver Disease N/A
Completed NCT04988204 - Diabetes Prevention Program for the Treatment of Nonalcoholic Fatty Liver Disease N/A
Recruiting NCT04369521 - Evaluation of the Effects of a Low Free Sugar Diet in Patients With Nonalcoholic Fatty Liver Disease N/A
Completed NCT01934777 - Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis Phase 3
Enrolling by invitation NCT00983463 - Abundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD)
Recruiting NCT00658164 - Effect of Iron Depletion by Phlebotomy Plus Lifestyle Changes vs. Lifestyle Changes Alone on Liver Damage in Patients With Nonalcoholic Fatty Liver Disease With Increased Iron Stores Phase 3
Recruiting NCT02148471 - Fatty Acids, Genes and Microbiota in Fatty Liver N/A
Completed NCT06441409 - Serum Ferritin Levels and Metabolic Dysfunction Associated Steatotic Liver Disease N/A
Completed NCT03656744 - A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM) Phase 2
Not yet recruiting NCT01735799 - THE ASSOCIATION BETWEEN FATTY LIVER (NAFLD) DISEASE AND PCOS N/A
Completed NCT01446276 - Long-term Investigation of Resveratrol on Fat Metabolism in Obese Men With Nonalcoholic Fatty Liver Disease N/A
Completed NCT00930384 - A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis N/A
Recruiting NCT02469272 - Fecal Microbiota Transplantation (FMT) in Nonalcoholic Steatohepatitis(NASH). A Pilot Study Phase 1
Completed NCT02132780 - Autonomic Dysfunction in Non-Alcoholic Fatty Liver Disease N/A
Terminated NCT01355575 - Rifaximin in Fatty Liver Disease Phase 4
Completed NCT01399645 - Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes Phase 2
Completed NCT01210989 - Trial of Hepaguard® in Adults With Nonalcoholic Steatohepatitis N/A